You are using an unsupported browser.
Some features of this site may not function properly. For optimal user experience, please view this site in Chrome, Firefox, Safari, or Edge.

SARS-CoV-2

Test Information
Home / Tests / Critical Infectious Diseases / Xpert MTB/RIF

Xpert® MTB/RIF

Accurate Detection of MTB and Rifampin Resistance Mutations

Ordering Info
Xpert<sup>®</sup> MTB/RIF

The Need


Great challenges face the global community, including the United States, with the worldwide re-emergence of TB and increased number of multi-drug resistant TB (MDR-TB) cases. The need for fast and accurate TB diagnosis with indication  for drug resistance is greater than ever.

Current MTB diagnostic methods require weeks to deliver a definitive result. Delayed results reporting can lead to patients placed in respiratory isolation unnecessarily or put on ineffective therapies. AFB smear could provide faster turn-around time, but may be missing the true positive cases and patients may continue to spread MTB to others in the community, increasing the disease burden.

The Solution


Xpert® MTB/RIF, on-demand molecular testing — an ideal solution:

  • On-demand results that empowers physicians to manage patients effectively
  • As few as one negative result can be used in the decision  to remove patient from respiratory isolation
  • Simultaneous detection of both MTB and rifampin resistance mutations, which are markers for MDR-TB strain
  • Acceptable samples include raw or concentrated sediments prepared from induced or expectorated sputum

The Impact


Impact on Patient Isolation Pathway
“Test and Release” or “Test and Treat”

/Site Images/Tests/mtbrif-pathway-updated.png

* Refer to the Xpert MTB/RIF package insert for details
^ Example with one Xpert® MTB/RIF negative result
# MOTT: Mycobacteria Other Than Tuberculosis; DST: Drug Susceptibly Test
1. FDA. New data shows test can help physicians remove patients with suspected TB from isolation earlier. Press Release. 2015 Feb 12. Accessed Feb 2021. https://wayback.archive-it.org/7993/20180126103209/https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm434226.htm
2. WHO. WHO endorses new rapid tuberculosis test. Press Release. 2010 Dec 8. Accessed Feb 2021. http://www.who.int/mediacentre/news/releases/2010/tb_test_20101208/en/
3. CDC. A New Tool to Diagnose Tuberculosis: The Xpert MTB/RIF Assay. Accessed Feb 2021. http://www.cdc.gov/tb/publications/factsheets/PDF/XpertMTB-RIFAssayFactSheet_Final.pdf
4. Davis JL, et al. Impact of GeneXpert MTB/RIF on patients and tuberculosis programs in a low-burden setting. a hypothetical trial. Am J Respir Crit Care Med. 2014 Jun 15;189(12):1551-9.
5. Lippincott CK, et al. Xpert MTB/RIF Assay Shortens Airborne Isolation for Hospitalized Patients With Presumptive Tuberculosis in the United States. Clin Infect Dis. 2014 Jul 15;59(2):186-92Workflow:3 Easy StepsUS-IVD. For In Vitro Diagnostic Use.231Pour

Ordering Info


Xpert® MTB/RIF

Standard 10-Test Kit

Catalog #: GXMTB/RIF-US-10
Back to Top